Platelet Rich Plasma for Regenerative Medicine Treatment of Bovine Ovarian Hypofunction by F. Cremonesi et al.
ORIGINAL RESEARCH
published: 13 August 2020
doi: 10.3389/fvets.2020.00517
Frontiers in Veterinary Science | www.frontiersin.org 1 August 2020 | Volume 7 | Article 517
Edited by:
Madhu S. Dhar,
The University of Tennessee, Knoxville,
United States
Reviewed by:
Francisco Miguel Sanchez Margallo,
Centro de Cirugía de Mínima Invasión
Jesús Usón, Spain
Marco Patruno,
University of Padua, Italy
*Correspondence:
Anna Lange-Consiglio
anna.langeconsiglio@unimi.it
Specialty section:
This article was submitted to
Veterinary Regenerative Medicine,
a section of the journal
Frontiers in Veterinary Science
Received: 17 April 2020
Accepted: 06 July 2020
Published: 13 August 2020
Citation:
Cremonesi F, Bonfanti S, Idda A and
Lange-Consiglio A (2020) Platelet Rich
Plasma for Regenerative Medicine
Treatment of Bovine Ovarian
Hypofunction. Front. Vet. Sci. 7:517.
doi: 10.3389/fvets.2020.00517
Platelet Rich Plasma for
Regenerative Medicine Treatment of
Bovine Ovarian Hypofunction
Fausto Cremonesi 1, Stefano Bonfanti 2, Antonella Idda 1 and Anna Lange-Consiglio 1*
1Dipartimento di Medicina Veterinaria, Università degli Studi di Milano, Milan, Italy, 2 Private Practitioner, Milan, Italy
Recent studies on cull cows have shown that ovarian abnormalities, particularly ovarian
insufficiency, are the main cause of reproductive failure. The aim of this study was to
treat bovine ovarian failure with intraovarian administration of autologous platelet rich
plasma (PRP), which is rich in growth factors, chemokines, and cytokines that could
stimulate follicular growth and steroidogenesis. Twelve cows with ovarian hypofunction
were enrolled in the study and they were randomly allocated in control group (CTR) and
treated group (six animal for group). In the treated group, only five animals received
the PRP treatment because intraovarian administration was hindered in one by a
rectovaginal fistula. Animals of control group were treated by intraovarian administration
of physiological solution. In the 4 weeks after PRP injection, a mild to strong increase
in progesterone (PRG) concentrations was detected in four of the five cows treated.
Artificial insemination (AI) resulted in four pregnancies that are still ongoing (7th month).
Intraovarian administration of PRP improved ovarian function after 2 months of treatment.
This effect may be due to reduction of follicular atresia or to revitalization of dormant
oocytes allowing restoration of fertility.
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INTRODUCTION
In recent years, the decline in fertility is negatively related to the increase in milk production in
dairy cattle and it is common worldwide. Indeed, to date there is a large scientific literature on the
sub-fertility of dairy cows (1). Recent studies showed that the main causes for low fertility in dairy
cows are reproductive disorders (2), mainly due to ovarian abnormalities. There are different kind
of ovarian disorders such as ovarian hypofunction, cystic ovarian disease, sub-oestrus, or silent
ovulation, and sub-luteal function. Although all ovarian disorders have an impact on profits, and
are a challenge for the dairy manager, this paper focuses on ovarian hypofunction and ovarian
failure.Within the different ovarian disorders, ovarian failure is the most common ovarian disorder
(11.45%) compared to cysts and adhesions (5.22 and 6.38%, respectively) (3).
Ovarian hypofunction is determined by the presence of follicles with a diameter of at least
8–15mm visible in two consecutive examinations, by the absence of a corpus luteum or cysts
without signs of oestrus in the 7-day period between the examinations (4).
During the bovine oestrous cycle, the development of antral follicle occurs through two or three
waves of follicular growth (5, 6). Follicles of 3–4mm diameter grow to about 6–8mm in diameter.
When the largest follicle reaches a diameter of 8.5mm (7), it begins its follicular dominance that
determines its size increment and the arrest of the smaller subordinate follicles. The dominant
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follicle will become the ovulatory follicle (8) and the luteinizing
hormone (LH) appears to regulate its function (9, 10).
Rapid LH pulse frequency (1 pulse/15–20min) is correlated
with the maturation and ovulation of the dominant follicle, on
the contrary, slow LH pulse frequency (1 pulse/3–5 h) results in
follicular atresia (11).
Ovarian hypofunction can be related to intermediate LH
frequencies (1 pulse every 1–2 h) due to different factors such
as low progesterone concentrations or heat stress (1). Usually,
these cows have a follicle of at least 8–15mm and absence of cysts
or luteal structures on two consecutive examinations during the
postpartum period, so it can be assumed that most cows affected
by ovarian hypofunction have ovarian anovulation.
Currently, these cows would be treated with gonadotropin
releasing hormone (GnRH)-based treatments such as the
Ovsynch protocol (4, 12, 13) or a progesterone releasing
intravaginal device (PRID) (14), but oestrus response in affected
cows is very low (usually <30%). There is clearly a need for
better reproductive strategies to reduce the economic impact of
decreased fertility. These strategies should increase the amount
of cyclic cows and the effectiveness of oestrus detection but most
importantly, improve ovarian function and completion of follicle
growth. Since the blocking of follicular growth results in a low
positive feedback to the hypothalamus, an alternative strategy
for treatment of ovarian failure could be an administration of
regenerative elements directly into the ovary, with the aim of
stimulating follicular growth and, consequently, steroidogenesis
in turn stimulating gonadotropin (FSH and LH) secretion.
This study proposes a novel therapeutic approach for
treatment of ovarian failure based on the regenerative properties
of PRP already well-documented in human (15, 16) and
veterinary (17, 18) medicine.
MATERIALS AND METHODS
The in vivo animal study was approved by the Milan University
Bioethics Committee n.118_2017, in accordance with 2010/63
EU directive on animal protection and Italian Law (D.L.
No. 116/1992) and following standard veterinary practice. An
authorization number 658/2020-PR of the Italian ministry of
health has also been obtained. Written informed consent from
the owners was also obtained to allow evaluation of the in vivo
effects of PRP in cows with ovarian failure.
Study Design
To investigate the effect of PRP in restoring ovarian function
in cows with ovarian failure, the study was divided into two
parts: (1) in vitro production of PRP; (2) in vivo intraovarian
PRP administration.
Abbreviations: AI, artificial insemination; EGF, epidermal growth factor;
FGF, fibroblast growth factor; GnRH, gonadotropin realizing hormone; HGF,
hepatocyte growth factor; IGF-I, insulin-like growth factor 1; LH, luteinizing
hormone; PDGFAA, PDGF-BB, PDGF-AB, platelet derived growth factors; PRG,
progesterone; PRID, progesterone releasing intravaginal device; PRP, platelet rich
plasma; TGF-β1, transforming growth factor β1; TGF-β2, transforming growth
factor β2; VEGF, vascular endothelial growth factor.
In vitro Production of PRP
Homologous platelet rich plasma was prepared from blood
collected from animals enrolled in the study. To produce
PRP, the blood was processed as described by Lange-Consiglio
et al. (17). Briefly: the site of blood collection was the
subcutaneous mammary vein. Blood (450ml) was collected in ad
hoc Terumo blood bags (Terumo Srl, Rome, Italy), containing
CPDA-1 and transported at +4◦C to the laboratory to be
immediately processed.
In aseptic conditions, the blood was drawn into sterile 50ml
Falcon tubes (Euroclone, Milan, Italy) and centrifuged at 100 ×
g for 30min. The result of centrifugation was the separation of
the blood into three components: red blood cells at the lowest
level, “buffy coat” in the middle layer, and platelet-rich plasma
(PRP) in the upper layer. The PRP was aspirated and centrifuged
again at 1,500 × g for 10min to obtain a platelet pellet and
the platelet poor plasma (PPP). The pellet was mixed in a PPP
volume to obtain a PRP at a standard concentration of 1 × 109
platelet/ml. All platelet counts on peripheral blood and PRP were
performed by an automatic hematology analyzer HeCoVet SEAC
(Florence, Italy).
The total volume of PRP obtained from each animal was
stored in syringes ready-to-use. The syringes were frozen at
−80◦C and thawed three times at 37◦C (19) to allow the
release of platelet derived factors. Syringes containing the dose
of 5ml of PRP were kept frozen at −80◦C until use. The
PRP was subjected to bacteriological examination to verify
its sterility.
In vivo Intraovarian PRP Administration
Animals
Animals enrolled in this study belonged to the same livestock
and their welfare conditions (related to housing, feeding, and
watering) were identical to those of the remaining animals of the
same farm.
This farm had an endowment of about 1,500 animals, with a
conception rate of 32% and pregnant rate of 19%. The ovarian
hypofunction affected about 10% of adult cows and, usually, it
was treated with the Ovsynch protocol with oestrus response
about of 25%. The average milk production of farm was of
34 l/die while the average of the animals affected by ovarian
hypofunction was of 38 l/die. The animal affected by this
pathology were more productive of the other animals.
Twelve Holstein–Friesian cows, 2–3 years old, with no
oestrus signs after the voluntary waiting period for breeding
(around 60 days), were monitored via cow podometers for two
oestrus cycles before being diagnosed as anoestrus. Ultrasound
examination (SonoSite Portable ultrasound with a 5.0 MHz
linear-array transducer, Inc, USA) confirmed bilateral ovarian
failure for all the subjects enrolled in the study. The animals
were randomly allocated in treated group with intraovarian
administration of PRP and in control group (CTR) with intra-
ovarian administration of placebo to confirm that the needle does
not cause trauma to the ovary. Each group was composed of
six animals.
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Setting
In this farm, the lactating cows were housed in bunks with a
concrete floor but with the availability of clean straw. The barn
was clean, airy, well lit, with shaded areas, fans, and watering
facilities. An automatic control system was used to remove dung
four times a day (at 6.00, 11.00, 18.00, and 23.00 h). Lactating
cows were fed twice a day during the experiment period (at
5.00 and 16.00 h) and received total mixed ration composed of
medical bandaged, medical dry, soybean flour, barley, cotton, and
cornmeal. This mixed ration was supplemented with milk and
silage. Mineral salt and water were provided ad libitum.
Intraovarian Injection of PRP or Placebo
In the treated group animal, the intraovarian PRP injection
was performed under ultrasound guidance using a Madison SA
600v instrument equipped with an ovum pick up probe (PB-
06VE65/20BD) as described by Cremonesi et al. (20). Each
animal was restrained in a cattle cage and clipped over the S5-
C1 vertebrae (5 × 5 cm). The area was cleaned three times with
alcohol and povidone-iodine. Then, sacrococcygeal (SC) epidural
anesthesia was induced with 4ml of Procaine hydrochloride 2%
(Procamidor, Richter Pharma Ag) and confirmed by loss of tail
tone. Before introduction of the ultrasound probe into the vaginal
fornix, the vulva was cleaned and the vagina lubricated. The
ovary was manually directed to the probe by rectal palpation. A
spinal 18G needle connected to a steel tube was inserted into the
probe needle guide and passed through the fornix to enter the
ovarian stroma to administer the PRP. Five cows received 5ml of
PRP with a concentration of 1 × 109 platelet/ml in each ovary.
A rectovaginal fistula in the sixth cow prevented access to the
ovaries and no PRP was administered in this cow.
The dose of PRP administered was calculated following the
procedures of Pantos et al. (21) and by tests carried out in our
laboratory with bovine ovaries recovered at the slaughterhouse.
In the control animal, the ovaries were injected with 5ml
of placebo (physiological solution: 0.9% NaCl) with the same
protocol of treated animals.
Data Measurement
A blood sample (10ml) was collected from the tail vein
of each cow before PRP or placebo treatment (week 0) to
measure progesterone (PRG) concentrations. Blood analysis was
repeated after 2 and 4 weeks of treatment. The blood was
refrigerated at 4◦C for 30min. The upper serum was then
collected by centrifugation for 10min (3,000 × g) and placed
in a −80◦C freezer. The plasma concentration of progesterone
was assessed using a quantitative automatedmethod based on the
enzyme-linked fluorescent assay (ELFA) technique (Mini-Vidas;
bioMérieux Italia S.p.A., Florence, Italy).
In the weeks following treatment, ovaries were monitored by
ultrasound and follicles or corpus luteum were detected in all
treated cows (Figure 1) but not in control animals.
Breeding experiments were performed when animals were
detected in oestrus. Artificial insemination, with cryopreserved
semen thawed for 30 s at 36–37◦C and evaluated for quality was
performed at 8–12 h after signs of oestrus. Frozen semen from the
same bull of proven fertility was used for artificial insemination
(AI) in all cows.
Pregnancy diagnosis was performed by ultrasound at 38, 56,
and 120 days.
The timeline of the study is shown in Figure 2.
Statistical Methods
Progesterone concentration data were analyzed with RStudio
Version 1.2.1335. Data normality was evaluated with Shapiro–
Wilk Normality Test. For non-normally distributed data,
Kruskal–Wallis non-parametric test was used. Differences were
considered statistically significant when p ≤ 0.05.
RESULTS
Only five animals of treated group were treated with intraovarian
administration of PRP because a rectovaginal fistula in one cow
prevented access to the ovaries.
In the 4 weeks after PRP injection, a mild to strong increase in
progesterone concentration was detected in four of the five cows
treated (Table 1). No variation in progesterone concentration
was detected in CTR animals (Table 2).
After 4 weeks, in cow number 70 the progesterone increased
4.8 fold (from 0.89 to 4.27 ng/ml). In cow 175, the increase was
11 fold (from 0.32 to 3.54 ng/ml). In cow 424, the progesterone
concentration remained unchanged (0.45–0.58 ng/ml). In cow
438, the progesterone increased 3.33 fold (1.87–6.23 ng/ml) and
in cow 1,078, there was a 3.97 fold increase (1.2–4.76 ng/ml).
Despite the numerical increases, there were no statistically
significant differences (p > 0.05) in progesterone concentrations
between week 0 and 4.
In four cows in which PRP administration was followed
by an increase in progesterone concentration, AI resulted in a
pregnancy that is still going (7th month) (Figure 3, diagnosis
at 38 days).
DISCUSSION
This study describes the administration of intraovarian PRP to
treat cows diagnosed with ovarian failure at the end of the
voluntary waiting period after their last parturition. One cow
was excluded from the study due to a rectovaginal fistula that
hindered the PRP injection.
The rational for application of PRP to hypo-functional ovaries
comes from its known properties in regenerative medicine.
Indeed, PRP is mainly used in human medicine to accelerate
the healing process following surgery (for example maxillofacial
surgery), in the repair of muscle and/or tendon, and in
the reversal of skin ulcers (16). In veterinary medicine, the
therapeutic use of PRP is still very limited. It has been mainly
used to promote equine tendon repair (22), to treat intestinal
wound healing in pigs (23), to cure a large cutaneous lesion in a
dog (24), in bovine mastitis (17) and in repeat breeder cows (18).
In all cases, PRP showed a clear regenerative potential due to its
amount of growth factors with mitogenic and anti-inflammatory
potential (16, 25). In particular, this hematic product can be
defined PRP only if it has a platelet concentration 3–5 fold higher
Frontiers in Veterinary Science | www.frontiersin.org 3 August 2020 | Volume 7 | Article 517
Cremonesi et al. Platelet Rich Plasma in Ovarian Hypofunction
FIGURE 1 | Ultrasound of ovaries. (A) Hypogonadal ovaries; (B) the arrow indicates 2 cm follicles; (C) the arrow indicates a corpus hemorrhagicum; (D) the arrow
indicates a corpus luteum.
than the physiological level. The PRP contains several growth
factors including the transforming growth factor β1 (TGF-
β1) and TGF-β2, platelet derived growth factors (PDGFAA,
PDGF-BB, and PDGF-AB), insulin-like growth factor 1 (IGF-
I), epidermal growth factor (EGF), vascular endothelial growth
factor (VEGF), fibroblast growth factor (FGF), and hepatocyte
growth factor (HGF). All these factors, which are stored in the
α-granules, are very important in the regeneration process. The
α-granules release their content following their breakdownwhich
can occur physically by temperature excursion (19) or by induced
platelet activation (26).
The regenerative effect of PRP in the reproductive field
was first muted by the Pantos group, which was able to
stimulate ovarian rejuvenation and obtain livebirths in peri-
menopausal women with infertility (27). These promising results
were expanded by Sills et al. (28), who performed intraovarian
administration of PRP in a clinic setting, without anesthesia,
using transvaginal ultrasound guidance, and confirmed by
Pantos et al. (21). These studies reported an increase in
serum AMH, decrease in FSH, fertilization via intracytoplasmic
sperm injection of collected oocytes, and generated blastocysts
suitable for banking or immediate embryo transfer. Pregnancies
were also reported (21, 28). The impact of PRP in treating
human reproductive disorders is also reported in some papers
describing its positive effect after intrauterine administration
in patients with repeated implantation failure (28) and chronic
endometritis (29).
In the veterinary field, a study performed by our team showed
that PRP induced an increase in progesterone receptors after
in vivo uterine administration in healthy cows and exerted
a modulatory effect on a range of molecules involved in
inflammation, which resulted in an anti-inflammatory effect in
an in vitro endometritis model (30).
During development, the ovary faces a variety of changes and
remodeling. The process of follicular growth begins from the
original oocyte that derived from primordial germ cells (31).
During embryogenesis, the ovarian cells of the female fetus are
delimited by granulosa cells to form primordial follicles (32).
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FIGURE 2 | Timeline of the study.
TABLE 1 | Dataset showing identification information for each treated cow
enrolled in the study (ID, age, lactation) and progesterone concentration and
pregnancy detection after intraovarian PRP injection.
Cow ID Age
(years)
N◦
lactation
Progesterone concentration
(ng/ml)
Pregnancy
after PRP
treatment
week0 week+2 week+4
70 3 2 0.89 1.57 4.27 Yes
175 2 1 0.32 0.31 3.54 Yes
424 4 3 0.45 2.63 0.58 No
438 3 2 1.87 1.14 6.23 Yes
779 5 4 Not treated because of rectovaginal fistula
1,078 2 1 1.2 5.67 4.76 Yes
TABLE 2 | Dataset showing identification information for each control cow
enrolled in the study (ID, age, lactation) and progesterone concentration and
pregnancy detection.
Cow ID Age
(years)
N◦
lactation
Progesterone concentration
(ng/ml)
Pregnancy
week0 week+2 week+4
321 2 1 0.47 0.65 0.82 No
267 2 1 0.45 0.75 0.69 No
643 3 2 0.37 0.66 0.84 No
185 4 3 0.77 1.03 0.82 No
482 3 2 0.86 0.66 0.49 No
947 3 2 0.49 0.79 0.85 No
Granulosa cells are necessary during follicular development (33,
34) and follicular atresia is probably mainly caused by granulosa
cell apoptosis.
Presumably, the PRP effect on ovarian dysfunction is due to
secretion of nutritional factors that produce beneficial effects on
follicles. To date, the mechanism of action on the ovary is not
entirely clear, but there are two main hypothesis that refer to
ovarian reserve. It is well-known that, at birth, the mammalian
female has a fixed ovarian that is dormant and closed in primary
follicles until the moment of activation, when growth andmeiotic
occur. The first hypothesis suggests that growth factors and
cytokines in PRP act on dormant oocytes exerting a revitalizing
effect and restoring fertility (28).
The other hypothesis supports the existence of ovarian germ
cells from which would be generated new oocytes (28). The
existence of ovarian stem cell and the detailed study of the
mechanisms underlying the PRP action is worthy of further
study, but goes beyond the scope of our preliminary work in this
animal model.
This study focused on empirical assessment of the efficacy
of PRP through measurement of progesterone (PRG) levels as
a marker for restored ovarian cycling and the monitoring of
oestrus to perform AI. Data reported in this study are certainly
limited but do support recent reports on the capacity to restore
physiological function of a malfunctioning ovary using PRP.
In particular, our data show that after intraovarian PRP
injection (week 0), the level of PRG increased between 3 and
11 fold during the subsequent 4 weeks (Table 1). This increase
in PRG concentration indicates recovery of ovarian cycling.
Presumably, in light of the large changes in PRG measured, each
cow had more than one ovulation during those 4 weeks. Artificial
insemination was performed when oestrus monitoring signaled
the heat. Artificial insemination was needed on more than one
occasion to obtain a pregnancy. As indicated in the right column
of Table 1, the time between PRP injection and the detection of
pregnancy varied for each cow and depended on the success of
AI. Pregnancy occurred only in the four cows that experienced
increased PRG levels. Only one animal failed to respond to PRP
treatment. Further studies including larger numbers of cows are
required in future studies.
No analysis of serum AMH or FSH levels was performed. This
could have added more accurate information on the temporal
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FIGURE 3 | Ultrasound at 38 day. The arrows indicate the embryo confirming pregnancy.
changes in the cows’ hormonal status but it is likely that a
rise in PRG corresponds to a decrease in FSH whilst, to date,
there are conflicting reports on the variable levels of AMH in
literature (35).
Usually, in this farm, the hypogonadism affects the 10%
of animals that are treated with the Ovsynch protocol, with
oestrus response about of 25%. In our study, we had performed
a different control group with intra-ovarian administration of
placebo to confirm that it was not the trauma caused by the
needle that awakened the ovarian activity but really the PRP. In
our opinion, the main platelet-derived mediators in improving
ovarian could be the PDGF, the TGF-β, and the HGF because
all these growth factors have mitogenic or trophic effects and,
specifically, the TGF-β that can stimulate cell proliferation and
differentiation. In this moment, it is no possible to affirm that the
ovarian activity is restored in the long time by PRP because the
four treated cows are pregnant and only after the delivery and the
voluntary waiting period for breeding, the oestrus signs will be
evaluated to confirm the efficacy of PRP in this pathology.
CONCLUSIONS
This is the first report of successful pregnancies after PRP
intraovarian injection in cows with ovarian failure. These
findings support the use of PRP in clinical practice, supplement
the literature regarding the use of PRP in a reproductive context,
and motivate the study of the fine mechanisms underlying
PRP action.
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